KRYS PE Ratio & Valuation,Is KRYS Overvalued

KRYS Relative Valuation

KRYS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KRYS is overvalued; if below, it's undervalued.

Historical Valuation

Krystal Biotech Inc (KRYS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 13.79 is considered Undervalued compared with the five-year average of -14.90. The fair price of Krystal Biotech Inc (KRYS) is between 378.98 to 416.27 according to relative valuation methord. Compared to the current price of 244.00 USD , Krystal Biotech Inc is Undervalued By 35.62%.

Relative Value

Fair Zone

378.98-416.27

Current Price：244.00

35.62%

Undervalued

34.42

26.37

EV/EBITDA

Krystal Biotech Inc. (KRYS) has a current EV/EBITDA of 26.37. The 5-year average EV/EBITDA is 12.69. The thresholds are as follows: Strongly Undervalued below -80.27, Undervalued between -80.27 and -33.79, Fairly Valued between 59.17 and -33.79, Overvalued between 59.17 and 105.65, and Strongly Overvalued above 105.65. The current Forward EV/EBITDA of 26.37 falls within the Historic Trend Line -Fairly Valued range.

28.02

EV/EBIT

Krystal Biotech Inc. (KRYS) has a current EV/EBIT of 28.02. The 5-year average EV/EBIT is 0.81. The thresholds are as follows: Strongly Undervalued below -62.75, Undervalued between -62.75 and -30.97, Fairly Valued between 32.59 and -30.97, Overvalued between 32.59 and 64.38, and Strongly Overvalued above 64.38. The current Forward EV/EBIT of 28.02 falls within the Historic Trend Line -Fairly Valued range.

13.79

Krystal Biotech Inc. (KRYS) has a current PS of 13.79. The 5-year average PS is 164.83. The thresholds are as follows: Strongly Undervalued below -994.80, Undervalued between -994.80 and -414.99, Fairly Valued between 744.64 and -414.99, Overvalued between 744.64 and 1324.46, and Strongly Overvalued above 1324.46. The current Forward PS of 13.79 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Krystal Biotech Inc. (KRYS) has a current P/OCF of 0.00. The 5-year average P/OCF is 41.14. The thresholds are as follows: Strongly Undervalued below -267.20, Undervalued between -267.20 and -113.03, Fairly Valued between 195.31 and -113.03, Overvalued between 195.31 and 349.48, and Strongly Overvalued above 349.48. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

23.93

P/FCF

Krystal Biotech Inc. (KRYS) has a current P/FCF of 23.93. The 5-year average P/FCF is -1.09. The thresholds are as follows: Strongly Undervalued below -222.48, Undervalued between -222.48 and -111.78, Fairly Valued between 109.60 and -111.78, Overvalued between 109.60 and 220.30, and Strongly Overvalued above 220.30. The current Forward P/FCF of 23.93 falls within the Historic Trend Line -Fairly Valued range.

Krystal Biotech Inc (KRYS) has a current Price-to-Book (P/B) ratio of 6.24. Compared to its 3-year average P/B ratio of 5.09 , the current P/B ratio is approximately 22.64% higher. Relative to its 5-year average P/B ratio of 4.40, the current P/B ratio is about 41.72% higher. Krystal Biotech Inc (KRYS) has a Forward Free Cash Flow (FCF) yield of approximately 2.33%. Compared to its 3-year average FCF yield of -1.26%, the current FCF yield is approximately -285.97% lower. Relative to its 5-year average FCF yield of -3.29% , the current FCF yield is about -170.95% lower.

6.20

P/B

Median3y

5.09

Median5y

4.40

2.33

FCF Yield

Median3y

-1.26

Median5y

-3.29

Competitors Valuation Multiple

The average P/S ratio for KRYS's competitors is , providing a benchmark for relative valuation. Krystal Biotech Inc Corp (KRYS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 16.65%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of KRYS increased by 55.10% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 32.42 to 81.15.

The secondary factor is the Revenue Growth, contributed 16.65%to the performance.

Overall, the performance of KRYS in the past 1 year is driven by Margin Expansion. Which is more sustainable.

16.65%

83.84M → 97.80M

Revenue Growth

150.31%

32.42 → 81.15

Margin Expansion

-111.86%

-307.85 → 36.51

P/E Change

55.10%

156.66 → 242.98

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Krystal Biotech Inc (KRYS) currently overvalued or undervalued?

What is Krystal Biotech Inc (KRYS) fair value?

KRYS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Krystal Biotech Inc (KRYS) is between 378.98 to 416.27 according to relative valuation methord.

How does KRYS's valuation metrics compare to the industry average?

What is the current P/B ratio for Krystal Biotech Inc (KRYS) as of Dec 16 2025?

As of Dec 16 2025, Krystal Biotech Inc (KRYS) has a P/B ratio of 6.24. This indicates that the market values KRYS at 6.24 times its book value.

What is the current FCF Yield for Krystal Biotech Inc (KRYS) as of Dec 16 2025?

As of Dec 16 2025, Krystal Biotech Inc (KRYS) has a FCF Yield of 2.33%. This means that for every dollar of Krystal Biotech Inc’s market capitalization, the company generates 2.33 cents in free cash flow.

What is the current Forward P/E ratio for Krystal Biotech Inc (KRYS) as of Dec 16 2025?

As of Dec 16 2025, Krystal Biotech Inc (KRYS) has a Forward P/E ratio of 34.65. This means the market is willing to pay $34.65 for every dollar of Krystal Biotech Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Krystal Biotech Inc (KRYS) as of Dec 16 2025?

As of Dec 16 2025, Krystal Biotech Inc (KRYS) has a Forward P/S ratio of 13.79. This means the market is valuing KRYS at $13.79 for every dollar of expected revenue over the next 12 months.

KRYS Valuation